The goal with ProKidney's rilparencel-branded therapy is “to demonstrate the therapy’s potential to preserve kidney function ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with ...

ProKidney Corp. (NASDAQ:PROK) saw its stock drop 11% in early trading before recovering somewhat to close down 3%, after ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Shares of ProKidney rose in early trading after it received FDA support for its path to accelerated approval of its rilparencel kidney disease drug. The stock was up 5.4% to $3.89 Tuesday and has more ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Investing.com -- ProKidney Corp (NASDAQ: PROK) stock jumped as high as 12% after the company announced that the U.S. Food and ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The Healthy.io, Geisinger and Boehringer Ingelheim partnership showed a 2.5x increase in test completion rates than standard clinical care.